Firmagon Uniunea Europeană - română - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degarelix - prostate neoplasme - terapia endocrină - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

FIRMAGON 120 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

firmagon 120 mg

fering gmbh - germania - degarelix - pulb.+solv. pt. sol. inj. - 120 mg - antagonisti hormonali si substante inrudite alti antagonisti hormonali si substante inrudite

FIRMAGON 80 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

firmagon 80 mg

fering gmbh - germania - degarelix - pulb.+solv. pt. sol. inj. - 80 mg - antagonisti hormonali si substante inrudite alti antagonisti hormonali si substante inrudite

Barrier Ultra Republica Moldova - română - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

barrier ultra

Îp barieră-profi, ucraina - imidacloprid, - soluţie pentru aplicarea cutanată - câini

Zgardă Inspector Republica Moldova - română - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

zgardă inspector

zao npf ecoprom, rusia - fipronil, - zgardă antiparazitară - câini, pisici

Degarelix Accord Uniunea Europeană - română - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - prostate neoplasme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.